findmyKOL

Jonathan Ungar, MD

Basic profile

Icahn School of Medicine at Mount Sinai

ORCIDNPI
RegionNew York, NY · NortheastSpecialtyDermatologyFocusDermatology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Jonathan Ungar is a Dermatology physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 76 publications with 999 citations (h-index 16).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
76publications

Distinct works indexed by OpenAlex, matched via ORCID.

999citations

Total citations across indexed works.

16h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
13companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

13 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    89%
    Porphyrin Precursor87.8%
    Aminolevulinic acid hcl100%
    Part B, office-administered43 patients
    Interleukin-17A Antagonist0.3%
    Cosentyx Sensoready (2 Pens)66%Taltz Autoinjector34%
    Part D<11 patients

    + 5 more classes in this area

  • Dermatology

    3.8%
    Corticosteroid2%
    Triamcinolone Acetonide84%Halobetasol Propionate9%Triamcinolone acetonide7%
    Part D + Part B<11 patients
    Interleukin-4 Receptor alpha Antagonist1.1%
    Dupixent Syringe58%Dupixent Pen42%
    Part D<11 patients

    + 4 more classes in this area

  • Sensory organs

    3.2%
    Corticosteroid3.2%
    Clobetasol Propionate53%Hydrocortisone37%Betamethasone Dipropionate10%
    Part D130 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”